CG Oncology CGON Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.08M+1,983% | $2.32M+409% | $1.67M+3,774% | -$0-100% | $52K-90.2% | ||
| $43.73M+59.2% | $29.96M+11.8% | $27.88M+42.1% | $31.33M+69.6% | $27.47M+59.6% | ||
| $20.78M+40.5% | $17.99M+53.7% | $23.33M+168% | $17.41M+132% | $14.79M+156% | ||
| $67.47M+59.7% | $51.02M+32.5% | $52.8M+86.3% | $48.74M— | $42.26M— | ||
| -$66.39M-57.3% | -$48.7M-28.0% | -$51.13M-80.7% | -$48.74M-88.5% | -$42.2M-87.8% | ||
| -6,130.1%+75,031pp | -2,097.3%+6,247pp | -3,069%+62,733pp | —— | -81,161.5%-76,914pp | ||
| $6.19M-20.2% | $7.39M+18.2% | $7.32M-7.2% | $7.32M+5.2% | $7.75M+40.1% | ||
| -$60.2M-74.7% | -$41.31M-29.9% | -$43.81M-115% | -$41.43M-119% | -$34.45M-103% | ||
| -5,558.8%+60,695pp | -1,779%+5,194pp | -2,629.5%+44,824pp | —— | -66,253.8%-63,053pp | ||
| -$0.71-57.8% | -$0.51-6.3% | -$0.57-90.0% | -$0.54-92.9% | -$0.45-25.0% | ||
| -$65.55M-55.4% | -$47.85M-25.8% | -$50.71M-79.4% | -$48.59M-88.0% | -$42.18M-87.8% | ||
| -6,052.4%+75,063pp | -2,060.8%+6,283pp | -3,044%+62,709pp | —— | -81,115.4%-76,869pp | ||
| -$66.39M-57.3% | -$48.7M-28.0% | -$51.13M-80.7% | -$48.74M-88.5% | -$42.2M-87.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is CG Oncology's revenue?
- CG Oncology (CGON) generated $5.1M in revenue over the trailing twelve months, up 666.0% year over year.
- Is CG Oncology profitable?
- CG Oncology is not currently profitable: it reported a net loss of $186.7M over the trailing twelve months, a -3682.6% net margin.
- What is CG Oncology's earnings per share?
- CG Oncology's diluted EPS over the trailing twelve months is $-2.33.
- Where does CG Oncology's income statement data come from?
- Every line is extracted from CG Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
